Laura Kreider Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 220 S 4th Ave, West Reading, PA 19611 Phone: 610-374-5175 Fax: 610-374-0426 |
Amanda Kalil Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 425 Buttonwood St, West Reading, PA 19611 Phone: 610-373-5166 |
Miss Patricia Stewart, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 396 Sunset Rd, West Reading, PA 19611 Phone: 610-374-6014 Fax: 610-374-6014 |
Alexis Shay Leiker Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 523 Reading Ave, Ste D1, West Reading, PA 19611 Phone: 484-258-9822 Fax: 484-334-7448 |
News Archive
New research has been published that focuses on the characterization of innate and adaptive immune responses in adult patients with different degrees of severity and also in pediatric patients with mild symptoms of COVID-19. In this study, researchers have developed an immune profile in children to understand the difference in COVID-19 infection in children and adults.
The global health nonprofit PATH has launched a five-year effort to make sure that new cervical cancer vaccines - the first vaccines developed and approved just for women's health - reach women in the developing world.
N-acetylcysteine (NAC) is a naturally occurring molecule that replenishes one of the body's antioxidants and now shows potential benefit as part of a standard course of treatment for patients with Parkinson's disease, according to a study published in the journal, Clinical Pharmacology & Therapeutics.
A receptor that is present in the nucleus of cells can, when activated, slow the growth of tamoxifen-resistant breast cancer cells, a new study found. The study built on the recent discovery that farnesoid X receptor — a nuclear receptor found mainly in the liver — is found in breast cancer tissue.
Led by researchers at Lawson Health Research Institute, a multi-centre registry trial is testing the use of a new imaging tracer, called a PSMA tracer, for early detection of recurrent prostate cancer. The registry gives patients access to a new type of imaging and will assess the impact on patient care.
› Verified 3 days ago